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Abstract
Early-life stress (ELS) in mice causes sustained hypomethylation at the downstream Avp enhancer, subsequent
overexpression of hypothalamic Avp and increased stress responsivity. The sequence of events leading to Avp enhancer
methylation is presently unknown. Here, we used an embryonic stem cell-derived model of hypothalamic-like differentiation
together with in vivo experiments to show that binding of polycomb complexes (PcG) preceded the emergence of ELS-
responsive DNA methylation and correlated with gene silencing. At the same time, PcG occupancy associated with the
presence of Tet proteins preventing DNA methylation. Early hypothalamic-like differentiation triggered PcG eviction, DNA-
methyltransferase recruitment and enhancer methylation. Concurrently, binding of the Methyl-CpG-binding and repressor
protein MeCP2 increased at the enhancer although Avp expression during later stages of differentiation and the perinatal
period continued to increase. Overall, we provide evidence of a new role of PcG proteins in priming ELS-responsive DNA
methylation at the Avp enhancer prior to epigenetic programming consistent with the idea that PcG proteins are part of a
flexible silencing system during neuronal development.
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Introduction
The hypothalamus harbors dynamic control systems that
govern a wide range of homeostatic processes including energy
balance, reproduction, and the response to stress. Structurally, the
hypothalamus is a complex neuroendocrine tissue composed of
different neuronal cell types that express classical neurotransmit-
ters and specific neuropeptides that act within the hypothalamus
and other brain regions to coordinate central and systemic
functions.
Developmental studies in mice, chick and zebrafish have
evidenced that sonic hedgehog (Shh) signaling plays an important
role in the induction and early patterning of the hypothalamus (for
review see [1]). Neuronal precursors giving rise to the paraven-
tricular (PVN) and supraoptic (SON) nuclei of the hypothalamus
first appear in the mouse between embryonic days 10 (E10) and 12
(E12). A portion of these neurons develop into the PVN while
others migrate laterally to form the SON between E13.5 and
E14.5 [2]. Neurons from these nuclei project their axons to the
posterior pituitary where they secrete the two neurohypophyseal
hormones arginine vasopressin (AVP) and oxytocin (OXT) in the
general circulation.
AVP plays a critical role in the regulation of fluid homeostasis,
blood pressure and the response to stress; the latter through its
stimulatory effects on the hypothalamic pituitary-adrenal (HPA)
axis (for review see [3,4]).
Experimental studies in rodents have demonstrated that early-
life stress and sustained stress in adulthood leads to enhanced
expression of hypothalamic Avp and an increase in the number of
Crh-containing neurons that co-express Avp (for review see [5]).
These findings suggest that Avp contributes at a given stage of life
and in a stressor-specific manner to the regulation of the HPA axis.
Consistent with this view, we have previously demonstrated that
early-life stress led to heightened stress responsivity in juvenile and
adult mice through epigenetic marking at the downstream
enhancer region of the Avp gene [6].
Molecular mechanisms that mediate epigenetic regulation of
gene expression comprise DNA methylation, chromatin (re-)
modeling and histone modifications (for review see [7]). DNA
methylation refers to the covalent bond of a methyl group at the
cytosine base of CpG dinucleotides catalyzed by DNA-methyl-
transferases (DNMTs) and generally serves to repress gene activity
on the long term. While Avp methylation at the downstream
enhancer did not differ between the PVN and SON, early-life
stress dependent neuronal activity selectively prevented binding of
the epigenetic reader Mecp2 (methyl-CpG binding protein 2) in
the PVN and resulted in increased Avp expression. Following on,
reduced Mecp2 occupancy at the Avp enhancer facilitated DNA
demethylation and thus gave rise to an enduring memory trace of
the initial stress event [8,9]. In view of these findings, we sought to
investigate in the present study the basic mechanisms that lay the
ground to Avp enhancer methylation and thus enable lasting
regulation by early-life stress.
The repressing activities of methylcytosine (5 mC) are mediated
by methyl-CpG-binding domain proteins (MBDs), which recruit
chromatin modifiers such as histone deacetylases (HDACs) or
methyltransferases (HMTs). Another group of proteins with an
important role in gene repression and development are the
polycomb (PcG) proteins. They assemble as multiprotein com-
plexes containing the core components EZH2 (enhancer of zeste
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homolog 2), SUZ12 (suppressor of zeste 12 homolog), and EED
(embryonic ectoderm development). Moreover, due to their
association with HDACs and DNA-methyltransferases (DNMT)
these complexes can confer transcriptional repression and stable
silencing of target genes.
To investigate the molecular events that contribute to ELS-
responsive DNA methylation at the Avp enhancer, we used here
an embryonic stem cell (ESC) derived model of hypothalamic-
like differentiation. Whereas neuropeptide expression patterns
were distinct from mice hypothalamus, Avp enhancer methyla-
tion faithfully evolved upon differentiation. Moreover, consis-
tent with the hypothesis that polycomb proteins (PCG) are part
of a flexible silencing system during neuronal development, we
evidence a new role in preceding experience-dependent gene
expression.
Materials and Methods
Animals
C57BL/6, Mecp2 wildtype or Mecp2 null male (-/y) mice [10]
were housed under 12 h daily illumination (lights on at 06:00) with
food and water ad libitum. All procedures on animals were
approved by the Regierung von Oberbayern and were in accord
with European Union Directive 2010/63/EU.
Cell culture
Rx-GFP K/I EB5 cells, a subline of the mouse embryonic stem
cell line EB5 (Riken cell bank depository; http://www.brc.riken.
jp/inf/en/index.shtml), were maintained in Dulbecco’s modified
Eagle medium (DMEM), 1% fetal bovine serum (FBS), 10%
KnockOut Serum Replacement (KSR), 0.1 mM non-essential
amino acids (NEAA), 1 mM sodium pyruvate (all from Invitrogen
Gibco), 0.1 mM mercaptoethanol and 2000 U/ml mouse leuke-
mia inhibitory factor (Lif; Millipore). For hypothalamic-like
differentiation, dissociated cells were grown as floating aggregates
in growth-factor free medium containing DMEM/F12, 1X
chemically defined lipid concentrate (Invitrogen), 5 mg/ml bovine
serum albumin (BSA, Invitrogen) and 450 mM alpha-monothio-
glycerol (MP biochemicals) on low cell-adhesion culture wells for 7
days. Cyclopamine (10 mM, Biozol) or purmorphamine (5 mg/ml,
Alexis) were added on the 4th day. Cells were cultured in DMEM/
F12, 7 g/litre glucose and 10% KSR for a further 3 days.
Hereafter, half the medium was replaced with DMEM/F12, 7 g/
litre glucose, N2, B27 and 10 ng/ml recombinant rat ciliary
neurotrophic factor (CNTF, Biozol) and grown for a further 15
days during which one half of the volume of culture was changed
every other day, following the protocol of [11]. Cells were also
treated with 0.5 mM or 5 mM 3-Deazaneplanocin A (DZNep)
(Cayman).
RNA extractions and RT-PCR
Total RNA and DNA were simultaneously extracted [12]
and reverse transcription (RT) reactions were done on 1 mg of
total cell culture-extracted RNA or 100 ng of tissue-derived
RNA with SuperscriptII (Invitrogen) and poly-dT primer.
Quantitative PCR (qPCR) was performed on a LightCycler
(Roche) using LightCycler Fast Start DNA Master SYBR
Green (Roche). Primer sequences for qPCR reactions are listed
in Table S1 in File S1. For all RT-PCR experiments the
expression of target genes was normalized to the geometric
mean of expression of three housekeeping genes [hypoxanthine
phosphoribosyltransferase (Hprt), glyceraldehyde-3-phosphate
dehydrogenase (Gapdh), and ATP synthase-coupling factor 6
(Atp5j)] to minimize variations due to different experimental
conditions.
Bisulfite sequencing
Genomic DNA (200–400 ng) isolated from PVN tissue punches,
hypothalami or cultured cells was digested with EcoRI, sodium
bisulfite converted (Qiagen DNA methylation kit), PCR amplified
and cloned into pGEM-T vector; at least 20 independent
recombinant clones per reaction and animal were analyzed on
an ABI Prism 3700 capillary sequencer. Bisulfite primers used for
qPCR analysis are listed in Table S2 in File S1.
ChIP experiments
Chromatin from cultured cells, mouse PVN punches (individual
pools formed from groups of 3) or whole hypothalami dissected
from fresh brains were cross linked, disrupted by sonification
(Diagenode BioruptorTM), and purified with the Magna ChIP G
kit (Millipore) as previously described [13]. Antibodies used were
anti-Suz12, anti-histone H3K27me3 (trimethyl-histone H3, Lys-
27), anti-histone H3K9me2 (dimethyl-histone H3, Lys-9) (each
from Diagenode; CS-029-100, pAb-069-050, pAb-060-050), anti-
H4Ac (panacetyl-histone H4) (Upstate; 06-866), anti-Rpol (acti-
vated RNA polymerase II) (Abcam; ab5131), anti-Dnmt1,
anti-Dnmt3a (both from Acris; AM20060PU-N, SM7028P), anti-
Dnmt3b, anti-Hdac1, anti-Hdac2 (each from Abcam; ab13604,
ab46985, ab51832), anti-5mC and anti-5hmC (both from Active
Motif; 61255, 39770). ChIP primers used for qPCR analysis are
listed in Table S3 in File S1.
Results
Differentiation of neuronal progenitors into
Avp-expressing neurons
In order to study basic mechanisms contributing to ELS-
responsive DNA methylation at the Avp enhancer, we chose a
cellular model of early hypothalamic-like neuronal differentiation.
Sonic hedgehog (Shh) plays a crucial role for the coordination of
diencephalic tissue growth with anteroposterior (AP) and dorso-
ventral (DV) patterning and the development of the PVN and
supraoptic nucleus (SON) from the lateral hypothalamus [14]. In
accord with these findings, hypothalamic-like precursors derived
from the embryonic stem cell line Rx-GFP K/I EB5 (hereafter
referred to as EB5) can be differentiated into rostral (Shh-treated)
or dorsal (Shh-depleted) hypothalamic-like progenitors that
subsequently give rise to ventral-medial and PVN/SON-like
neurons [11].
Cultivation of EB5 cells in suspension under serum free
conditions and in the absence of insulin or other exogenous
growth factors resulted in the rapid down-regulation of pluripo-
tency factors (Figure 1A) followed by the up-regulation of
hypothalamic proneuronal factors (Figure 1B). Moreover, treat-
ment with the Shh antagonist cyclopamine promoted increased
expression of genes specific for the dorsal hypothalamus and the
PVN, including the neurohypophyseal peptides Avp and Oxytocin
(Oxt) (Figure 1C). The importance of Shh inhibition was
corroborated by application of a Shh agonist (purmorphamine)
that inhibited the expression of markers characteristic for the PVN
such as Brn2 and Arnt2 (Figure 1D).
Together, these experiments suggested that hypothalamic-like
differentiation of EB5 cells can serve as a suitable model to
investigate molecular mechanisms underlying Avp enhancer
methylation.
Polycomb and DNA Methylation at the Avp Enhancer
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DNA methylation of the Avp enhancer during
hypothalamic-like differentiation
Having established a cellular model for hypothalamic-like
development and Avp expression, we sought to characterize the
events that precede the appearance of ELS-responsive DNA
methylation at the Avp enhancer. Analysis of DNA methylation at
the ELS-responsive CpG residues revealed a strong increase in
methylation following differentiation through withdrawal of Lif,
(Figure 2A) which was maintained following cyclopamine treat-
ment. Importantly, Avp enhancer methylation of Lif-withdrawn
EB5 cells closely matched the methylation profiles from mouse
PVN and SON (Figure 2B), [6]. Moreover, the promoter and gene
body of the Avp gene remained unmethylated during all phases of
hypothalamic-like differentiation of EB5 cells consistent with the in
vivo findings in mice (data not shown). Therefore, DNA
methylation at the Avp locus seemed to be conserved between
different Avp-expressing brain nuclei (i.e. PVN versus SON) and
an in vitro model of hypothalamic-like differentiation. However,
Avp expression was undetectable during early hypothalamic-like
differentiation and depended on further treatment with the Shh-
antagonist cyclopamine which favors the formation of PVN/SON-
like neurons (Figure 1C) [11].
As controls, for proper DNA methylation during hypothalamic-
like differentiation, we compared the results from the Avp gene to
those from the pluripotency marker Nanog and two classes of repeat
elements. The Nanog promoter showed a strong increase in DNA
methylation following 4 days of Lif withdrawal (Figure S1 in File
S1) that correlated with a corresponding reduction in gene
expression (Figure 1A) [15]. Similarly, the LINE1 repeat [16]
element strongly gained in methylation, as previously reported. In
contrast, methylation at the IAP element [17] remained un-
changed irrespective of either treatment (Figure S1 in File S1).
Together, these results indicate that methylation of the Avp
enhancer emerged prior to and irrespective of gene expression
during early hypothalamic-like differentiation. At opposite, the
Nanog gene and the LINE1 elements were barely methylated in
their on-states, while increased DNA methylation associated with
their off-states. Such gene silencing serves on the one side in case
of Nanog to shut-off a pluripotency gene during differentiation and
on the other side to restrain the potential for self-replication of
LINE1 elements which undergo uniform methylation in differen-
tiated somatic tissues.
Consistent with the results from above, DNA methylation
appeared at the Avp enhancer at embryonic day seventeen (E17) to
increase a further 20% until birth and a further 20% thereafter
until 6 weeks of age (Figure 2C). Hereafter, Avp methylation
gradually declined with age [18].
Avp expression was undetectable at E17, increased peri- and
postnatally and increased further in adulthood with the greatest
significant change for Avp occurring between E17 to the perinatal
Figure 1. Hypothalamic-like differentiation of the embryonic stem cell line EB5. A, Pluripotency factors rapidly decreased in differentiating
EB5 cells over 4 days following withdrawal of leukemia inhibitory factor (-Lif) as evidenced by qRT-PCR analysis. B, Markers for neuroectoderm and
rostral hypothalamic development conversely increased during EB5 cell differentiation. C, qRT-PCR analysis of markers for dorsal-ventral
hypothalamic patterning and PVN neurons demonstrated strong increases following 25 days of differentiation. D, PVN markers (Brn2 and Arnt2)
further increased following treatment with the sonic hedgehog (Shh) antagonist cyclopamine as evidenced by qRT-PCR. Application of the Shh
agonist purmorphamine blocked this increase. Bars represent standard deviations from the mean (sem) from at least 3 independent experiments.
doi:10.1371/journal.pone.0090277.g001
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time point (Figure 2D). Thus, ELS-responsive DNA methylation
precedes Avp expression in vivo in agreement with the results from
early hypothalamic-like differentiation of EB5 cells. Moreover,
increases in Avp expression concurred with higher CpG methyl-
ation at the enhancer. At odds with these findings, DNA
methylation is, however, generally viewed to silence gene
transcription.
Histone marking of Avp during hypothalamic-like
differentiation
The repression of Avp expression together with low levels of
methylation at the enhancer in undifferentiated EB5 cells
suggested the presence of a mechanism that prevents gene
transcription before the emergence of ELS-responsive DNA
methylation. We therefore investigated the role of another
regulatory mechanism, namely post-translational histone modifi-
cations. These marks form complex signatures controlling open
and closed chromatin configurations corresponding with activa-
tion and repression of gene transcription, respectively. We used
chromatin immunoprecipitation (ChIP) experiments to track
changes in histone marks at the Avp locus during hypothalamic-
like differentiation of EB5 cells (Figure 3A). At the Avp promoter
low levels of the repressive histone marks H3K27me3 (trimethyl-
histone H3 Lys-27) and H3K9me2 (dimethyl-histone H3 Lys-9)
decreased concomitantly to an increase in the active mark H4Ac
(panacetyl-histone H4), (Figure 3B). A similar picture emerged for
the gene body with more pronounced changes in either mark
when compared to the promoter region (Figure 3C). Furthermore,
high levels of H3K27me3 at the enhancer region strongly declined
concurrently to a robust increase in H4Ac (Figure 3D). The
transition from repressive to active chromatin marks correlated
with the recruitment of activated RNA polymerase II (Rpol) across
the Avp gene indicative of the formation of an open chromatin
structure permissive to transcription.
Together, these findings suggested the presence of a repressive
chromatin domain at the Avp enhancer that seemed to prevent
precocious expression prior to DNA methylation. Therefore, we
Figure 2. Hypothalamic-like differentiation triggered ELS-responsive DNA methylation at the Avp enhancer. A, ELS-responsive DNA
methylation rapidly evolved following 4 days of Lif withdrawal and was maintained during subsequent cyclopamine treatment as evidenced by
bisulfite sequencing of 25 clones. Shaded hemispheres represent percentage of methylation at each ELS-responsive CpG residue. Results are
representative of three independent experiments. B, Comparison of ELS-responsive DNA methylation at the Avp enhancer in the SON, PVN and
following hypothalamic-like differentiation of EB5 cells. C, Overall CpG methylation at CpG island 3 (CGI3) comprising the ELS-responsive Avp
enhancer in the developing mouse hypothalamus. Postnatal days (PND) are indicated. D, Avp mRNA expression as evidenced by qRT-PCR analysis in
the developing mouse dorsal hypothalamus. Bars represent standard deviations from the mean (sem), from 4–5 independent experiments.
doi:10.1371/journal.pone.0090277.g002
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next sought to identify the mechanisms directing the establishment
of repressive histone marks at the Avp enhancer.
The histone mark H3K27me3 is a hallmark of the polycomb
repressive complex 2 (PRC2), a class of polycomb-group proteins
(PcG), that play a major role throughout development by
dynamically switching on and off gene expression programs
through interactions with the epigenetic machinery [19]. The
methyltransferase Suz12 is part of the PRC2 complex and
represents the catalytic subunit that maintains histone methylation
patterns throughout DNA replication due to its ability to bind
unmethylated DNA and mediate gene silencing through methyl-
ation of H3K27 [20].
Therefore, we asked whether the presence of H3K27me3
relates to Suz12 occupancy at the Avp locus. Suz12 binding was
barely detectable at the Avp promoter (Figure 3B) whereas high
levels of binding occurred at both the gene body and enhancer
(Figure 3C, 3D) and strongly decreased in either case following
differentiation.
The binding of Suz12 to wingless (Wnt1), a beta-catenin
dependent developmental regulator and to the RNA polymerase
II promoter (RNAPII), a housekeeping gene, served as positive and
negative controls, respectively, in these experiments (Figure S2 in
File S1) [21].
Tet proteins prevent ELS-responsive DNA methylation
Having established the mechanism of Avp repression in
undifferentiated neuronal progenitors, we next sought to under-
stand how the ELS-sensitive enhancer region is primed for
subsequent DNA methylation. During hypothalamic-like differen-
tiation, expression of Suz12 decreased by 5-fold (Figure 4A) whilst
its 10- and 2-fold decreased binding at the Avp enhancer and Wnt1
promoter, respectively (Figure 3B and Figure S2 in File S1,
respectively) was suggesting an active mechanism by which Suz12
is excluded from the former. With respect to the Avp enhancer, one
Figure 3. Hypothalamic-like differentiation displaced repressive histone marks and Suz12 occupancy at the ELS-responsive Avp
enhancer. A, Schematic diagram of the Avp locus. Exons are shown as boxes and numbered with coding parts shadowed. Amplified DNA segments
depicted above. Arrow marks translational start codon. ChIP analysis was done for the promoter, gene body and downstream enhancer regions. The
strong-CpG island at the gene body and the intermediate-CpG island harboring the ELS-responsive enhancer are shown beneath by black and grey
bars, respectively. B–D, Chromatin samples from undifferentiated (+Lif), Lif-withdrawn (-Lif) and further cyclopamine treated EB5 cells were
immunoprecipitated with antibodies against activated RNA polymerase II, Suz12, H3K27me3 (trimethylation-histone H3, Lys27), H3K9me2
(dimethylation-histone H3, Lys 9), and H4Ac (pan-acetylated-histone H4). Recovered DNA was analyzed by qPCR for the presence of the Avp promoter
(B), gene body (C) or enhancer (D). Bars represent standard deviations from the mean (sem),*, P,0.05; from 4 independent experiments.
doi:10.1371/journal.pone.0090277.g003
Figure 4. Expression of Suz12 and Tet genes correlated with the
presence of methylcytosine (5mC) and hydroxymethylcytosine
(5hmC) at the Avp locus during hypothalamic-like differentia-
tion. A, Suz12 gene expression rapidly decreased following 4 days of Lif
withdrawal. B, Similarly, Tet1 and Tet2, but not Tet3, gene expression
rapidly declined following 4 days of Lif withdrawal. C, MeDIP showed
high hydroxymethylation (5hmC) at the Avp gene body and down-
stream enhancer which strongly decreased upon Lif-withdrawal.
Application of cyclopamine evoked a further decline at the enhancer
region. D, Conversely, methylation (5mC) at the Avp enhancer, but not
at the gene body, increased as evidenced by MeDIP. Bars represent
standard deviations from the mean (sem), *, P,0.05; from3 indepen-
dent experiments performed in duplicate.
doi:10.1371/journal.pone.0090277.g004
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likely mechanism is the onset of DNA methylation at this region,
which is thought to interfere with Suz12 binding [20].
The Tet (ten eleven translocation) protein family members –
comprising Tet1, Tet2 and Tet3 – share the capacity to convert 5-
methylcytosine (5mC) into 5-hydroxymethylcytosine (5hmC) to
initiate a process of active DNA demethylation. In addition to the
conserved catalytic subunit, Tet1 and Tet3 also have a DNA-
binding domain previously described as a CpG-binding motif [22].
Hereby, Tet1, being mainly expressed in ESCs, contributes to
gene silencing by facilitating recruitment of PcG proteins to CpG-
rich gene promoters.
We found that during hypothalamic-like differentiation of EB5
cells Tet1 sharply decreased, as was the case for Tet2, while Tet3
increased slightly in expression (Figure 4B). We then used
immunoprecipitation of methylated DNA (MeDIP) to assess
changes in methylation using antibodies against 5mC and
5hmC. Consistent with a role in DNA demethylation, 5hmC,
the product of Tet proteins, decreased rapidly at both the Avp gene
body and enhancer during differentiation followed by an increase
in methylation only at the enhancer (Figure 4C, 4D).
Together, these data suggest that PCR2 occupancy at the Avp
gene body and enhancer depends on the enzymatic activities of
Tet proteins preventing precocious DNA methylation. In turn,
neuronal differentiation appears to trigger the eviction of PcG
proteins concomitant with the encroachment of DNA methylation
at the enhancer region.
DNA-methyltransferase and Mecp2 binding at the
ELS-responsive Avp enhancer
DNA methylation is catalyzed by a family of DNMTs, classified
either as de novo methyltransferases that recognize previously
unmethylated CpG sequences, or maintenance methyltransferases
that copy preexisting methylation marks onto new DNA strands
during replication.
Consistent with the scenario from above that differentiation
associates with the accumulation of DNA methylation at the Avp
enhancer the expression of the de novo methyltransferaseDnmt3a,
increased during EB5 cell differentiation and in the postnatal
hypothalamus (Figure 5A, 5B). In contrast, the expression of the
maintenance methyltransferase Dnmt1 was largely unaffected
under both conditions. Importantly, Dnmt3a occupancy increased
selectively at the Avp enhancer while binding at either the
promoter or gene body remained unaltered (Figure 5C). This
finding demonstrated that increases in Dnmt3a expression were
not sufficient to promote per se DNA methylation but seemed to
require selective recruitment to the enhancer region.
In accord with this idea Dnmt3a occupancy at the Avp enhancer
did not change following cyclopamine treatment (Figure 5C)
which led to a further increase in Dnmt3aexpression (Figure 5A).
Together, these results indicated that Dnmt3a recruitment at the
Avp enhancer was ‘‘actively’’ controlled and took place during the
formation of hypothalamic-like progenitors.
The family of methyl-CpG-binding domain proteins (MBD)
serves as an important mediator to couple DNA methylation to
repressive chromatin configurations. The expression of the family
members Mecp2, Mbd1 and Mbd2 increased concurrently to
Dnmt3a during differentiation (Figure 5A), whereby increases in
Mbd1 and Mbd2 surpassed the one of Mecp2. Interestingly,
however, this led only to an increase of Mecp2, but not of
Mbd1 and Mbd2, occupancy at the enhancer (Figure 5C, data not
shown) and thus corroborated our previous finding that Mecp2
and other MBDs bound in a rather mutually exclusive manner
across the Avp locus. This behavior is likely to reflect the presence
of high-affinity MeCP2 binding sites at the Avp enhancer region as
previously described [6,23].
Histone deacetylases mediate transcriptional repression by PcG
[24], Dnmts [25] and also Mecp2 [26]. Consistent with this view,
Lif withdrawal halved Hdac1 and Hdac2 occupancy at the Avp
enhancer and supported the hypothesis that PcG binding
contributes to the recruitment of Hdacs at the Avp enhancer.
Mecp2 binding depends on prior Suz12 occupancy
Concurrent to the loss of Suz12 occupancy (Figure 3B), Mecp2
binding at the Avp enhancer increased during hypothalamic-like
differentiation (Figure 5C). In order to understand the relationship
between these two factors, we tested the effects of DZNep, a potent
S-adenosylhomocysteine (AdHcy) hydrolase inhibitor that leads to
the depletion of Suz12 and PRC2 protein complex formation [27].
In accord with this report, treatment of naı¨ve EB5 cells with
DZNep resulted in decreased Suz12occupancy at the Avp
enhancer and a subsequent reduction in Mecp2 recruitment
during hypothalamic-like differentiation. In contrast, DZNep
treatment of differentiated cells elicited no effect on Mecp2
binding at the Avp enhancer, suggesting that depletion of Suz12
during the embryonic state is an important step prior to Mecp2
recruitment (Figure 6A). Compatible with this view, PcG protein
complexes can directly interact with Dnmts and recruit them to
their target genes [28,29]. In support of this scenario, MeDIP
analysis of DZNep treated EB5 cells showed reduced methylation
of the ELS-responsive CpG residues at the Avp enhancer region
when applied prior to differentiation (Figure 6B).
Mecp2 binding associates with repressive chromatin
marks at the Avp enhancer
Mecp2 had been originally identified as a protein that
specifically binds to methylated DNA to confer gene silencing.
More recent work suggested, however, an additional role as
activator of gene transcription in hypothalamic tissues (for review see
[30]).
In view of the finding from above that Mecp2 binding at the Avp
enhancer followed polycomb silencing and that Avp expression
increased at the same time, we asked whether Mecp2 acts to
enhance Avp expression, or alternatively, to restrain expression
subsequent to the dissociation of the repressor complex. Using
sequential ChIP (seqChIP) we found Mecp2 preferentially in the
chromatin fraction precipitated with H3K9me2, a mark of
transcriptionally inactive chromatin, when compared to H3Ac
(panacetyl-histone H3), an active mark, in both the PVN
(Figure 7A) and SON (data not shown), demonstrating enrichment
of Mecp2 in chromatin containing repressive histone marks.
Mecp2 deficient mice (-/y) served as a control for the specificity of
the Mecp2 antibody in seqChIP experiments (Figure 7B). More-
over, we detected about 2-fold higher amounts of the active mark
H3Ac concomitant with about 3-fold lower amounts of the
repressive mark H3K9me2 in Mecp2 deficient mice (-/y)
consistent with the hypothesis that Mecp2 occupancy favors the
formation of a repressive chromatin complex at the Avp enhancer
(Figure 7B).
Compatible with these findings, Mecp2 associated with the
chromatin fraction containing the de novo methyltransferases
Dnmt3a and Dnmt3b, but not Dnmt1, and to less degree with
Hdac 1 and 2 at the Avp enhancer in mouse hypothalamus
(Figure 6C). Together, these results suggest that Mecp2 binding at
the Avp enhancer following polycomb displacement promotes the
recruitment of Dnmts and Hdacs (Figure 8) and thus opens up the
possibility to relieve gene repression through ELS-dependent
phosphorylation and dissociation of Mecp2.
Polycomb and DNA Methylation at the Avp Enhancer
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Figure 5. Dnmt3a and Mecp2 associated at the Avp enhancer during differentiation. A, Dnmts, Mecp2, Mbd1 and Mbd2 mRNA expression
during hypothalamic-like differentiation of EB5 cells as evidenced by qRT-PCR analysis. B, Expression of Dnmts and Mecp2 RNAs in the mouse
hypothalamus. C, Binding of Dnmts, Mecp2 and Hdacs at the Avp locus during hypothalamic-like differentiation. Chromatin samples from
undifferentiated, Lif-withdrawn and further cyclopamine treated EB5 cells were immunoprecipitated with antibodies against Dnmt1, Dnmt3a,
Dnmt3b, Mecp2, Hdac1 and Hdac2. Recovered DNA was analyzed by qPCR for the presence of the Avp promoter, gene body or downstream
enhancer.
doi:10.1371/journal.pone.0090277.g005
Figure 6. A, DZNep treatment inhibited Suz12 occupancy and Mecp2 recruitment at the Avp enhancer during hypothalamic-like differentiation of
EB5 cells. Chromatin samples from cells treated with DZNep during differentiation were immunoprecipitated with antibodies against Suz12, Mecp2 or
H4Ac and recovered DNA analyzed by qPCR for the presence of the Avp enhancer. Cells treated with DZNep (DZ) in the undifferentiated state for
24 hrs (+Lif) showed strongly reduced Suz12 binding. Following 4 days of differentiation (DZ,-Lif 4 days), Mecp2 binding was decreased while H4Ac
was increased. In contrast, following 3 days of differentiation an additional 24 hours application of DZNep (-Lif 4days, DZ) did not affect Mecp2
occupancy. B, DZNep treatment led to reduced methylation at the Avp enhancer. MeDIP evidenced reduced 5hmC at the downstream enhancer in
response to increasing doses of DZNep, while methylation levels at the promoter and gene body regions did not change. Bars represent standard
deviations from the mean (sem), *, P,0.05; from 5 independent experiments performed.
doi:10.1371/journal.pone.0090277.g006
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Discussion
Here we showed that PcG occupancy at the Avp locus silences
early gene expression and precedes the emergence of ELS-
responsive DNA methylation at the enhancer region. Dissociation
of PcG complexes triggered DNA methylation and subsequent
Mecp2 occupancy. Consistent with a role to restrain Avp
expression, Mecp2 bound to chromatin enriched in Dnmts and
Hdacs. Together, these findings extend the spectrum of action of
PcG proteins to prime experience-dependent DNA methylation.
Given the tiny amounts of hypothalamic tissue available from
embryonic mice precluding most of the molecular experiments
reported here, we opted for a cellular model of hypothalamic-like
differentiation to conduct a comprehensive series of functional
studies. In parallel, correlations with mice hypothalamic develop-
ment were sought for by appropriate gene expression and
molecular studies wherever feasible.
Using an ESC-derived model of hypothalamic-like differentia-
tion we discovered that Avp silencing in the undifferentiated state
concurred with PcG occupancy at the gene body and ELS-
responsive enhancer region. PcG proteins were originally identi-
fied as part of a stable, epigenetic cellular memory system that
controls gene silencing via chromatin structure. In addition to their
role as epigenetic gatekeepers, recent reports suggest that PcG
proteins are also involved in controlling dynamics and plasticity of
gene regulation, particularly during differentiation, by interacting
with various components of the transcriptional machinery [19].
These findings raised the possibility that PcG protein complexes
also contribute to experience-dependent programming of Avp
expression. In the present study, we showed, however, that
following hypothalamic-like differentiation of ESCs, PcG proteins
dissociated from the Avp locus concomitant to de novo DNA
methylation at the downstream enhancer.
Consistent with a functional link between PcG occupancy and
de novo methylation [32], depletion of PcG proteins through
DZNep treatment prior to hypothalamic-like differentiation
reduced the appearance of ELS-responsive methylation at the
Avp enhancer. PcG protein complexes associate with Tet proteins
[31], Hdacs [24] and also Dnmts [28,29], whereby the balance
between Tet proteins (driving demethylation) and Dnmts (driving
methylation) is critical to the maintenance or loss of PcG
occupancy [31].
Although we evidenced PcG occupancy at the Avp gene body
(high-CpG frequency island) and the downstream enhancer
(intermediate-CpG frequency island), Dnmt3a occupancy and de
novo methylation was targeted to the Avp enhancer consistent with
the idea that de novo methylation of CpG islands occurs primarily
at weak-CpG islands leading to gene silencing [32]. In further
support of our present findings non-promoter methylation by
Dnmt3a has been implicated as critical in antagonizing PcG
repression and inducing active chromatin states of neurogenic
genes [33].
Treatment with the Shh antagonist cyclopamine, giving rise to
PVN/SON-like neurons, promoted Avp expression despite pre-
served enhancer methylation. Moreover, Avp expression and
enhancer methylation increased both postnatally until adulthood.
Figure 7. Mecp2 occupancy at the Avp enhancer coupled with
repressive chromatin marks and repressor complexes. A,
Chromatin samples from the PVN were subjected to seqChIP. The first
ChIP was done with antibodies against H3Ac (panacetylated-histone
H3), an active mark, and H3K9me2 (dimethyl-histone H3, Lys-9), a
repressive mark. The second round ChIP was carried out with anti-
Mecp2. Hereby, Mecp2 was preferentially, with a distinct trend toward
significance, contained in the chromatin fraction associated with the
transcriptionally inactive Avp enhancer. B, PVN tissues from Mecp2 null
male (-/y) mice showed increased H3Ac and decreased H3K9me2
chromatin marks at the Avp enhancer compatible with a repressor
function of Mecp2. However, due to the knockout of Mecp2, the anti-
Mecp2 antibody did not enrich for either chromatin fraction attesting to
its specificity. C, Sequential ChIP experiments showed that Mecp2
occupancy at the ELS-responsive enhancer associated with the
chromatin fraction containing Hdacs and Dnmts. Chromatin samples
from hypothalamus were immunoprecipitated in the first ChIP
experiment with antibodies against Hdac1, Hdac2, Dnmt1, Dnmt3a
and Dnmt3b. Following on two-thirds of the product of the primary
ChIP were precipitated in the second ChIP with anti-C-terminal Mecp2;
the remaining sample was used for the analysis of the primary ChIP.
DNA recovered from both ChIP steps was analyzed by qPCR for the
presence of the Avp enhancer. Bars represent standard deviations from
the mean (sem), *, P,0.05; #, P,0.07 from 5 independent experiments
performed.
doi:10.1371/journal.pone.0090277.g007
Figure 8. Model for the formation of early-life stress responsive DNA methylation. In the undifferentiated state, Tet1 and polycomb
complexes (for the sake of simplicity symbolized by the histone methyltransferase Suz12) bind to the Avp enhancer and confer gene silencing.
Hereby, Tet1 catalyzes the hydroxylation of methylated CpG residues (mCpGR 5hmC) in favor of further demethylation and maintained polycomb
occupancy. Upon hypothalamic-like differentiation, polycomb and Tet1 proteins dissociate and lead to an increase in Avp enhancer methylation.
Subsequently, recruitment of Mecp2 together with Hdacs and Dnmts enforces the formation of CpG methylation and repressive histone marks
restraining Avp expression. Overall, Avp enhancer methylation does not serve as an ‘on-off switch’ but enables programming of Avp expression in
response to early-life stress.
doi:10.1371/journal.pone.0090277.g008
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Together, these findings suggest that DNA methylation at the Avp
enhancer does not fulfill a role as an ‘on-off’ switch of gene
expression. Instead, Avp enhancer methylation can serve to fine-
tune gene expression levels in response to environmental signals.
In support of this view, hypothalamic Mecp2 expression
increased during perinatal/postnatal development in the mouse
and rat [34]; a period crucial for epigenetic programming of Avp.
Upon binding to the Avp enhancer, Mecp2 associated with Hdacs
and Dnmts, in particular Dnmt3a, the expression of which
increased perinatally in the hypothalamus. As a result, Mecp2
occupancy at the Avp enhancer correlated with repressive
chromatin marks supporting its role in repression [6].
Understanding the molecular basis by which cells form and
maintain their memory represents an ongoing task. Epigenetic
mechanisms such as DNA methylation can alter gene expression
in response to the environment and thus the intrinsic properties of
neurons in a long-term fashion, perhaps on the order of years
[9,35]. Here we provide insight in the mechanisms leading to ELS-
responsive DNA methylation at the Avp enhancer in an in-vitro
model of hypothalamic-like differentiation and assign an impor-
tant role to PcG proteins. In this respect, our present work
describes how mechanisms operating during early cellular
development (i.e. PcG proteins) intersect with mechanisms
mediating early-life experiences (i.e. Mecp2). Overall, we suggest
that cell memories can evolve gradually over time by recruiting
and building up on the mechanism available at a given age.
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